Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Technical Presentation (December 2019)

9 slides from Evofem Biosciences's technical presentation, Dec 2, 2019

  1. Slide 1: AMPREVENCE Data Results

    Exhibit 99.2 Evofem Biosciences AMPREVENCE Data Results December 2, 2019 Nasdaq: EVFM

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,

  3. Slide 3: AMPREVENCE Trial Key Take-Aways

    AMPREVENCE Trial Key Take-Aways  Study met primary and secondary endpoints with statistical significance – PRIMARY: 50% relative risk reduction in urogenital chlamydia infection – SECONDARY: 78% relative risk reduction in urogenital gonorrhea infection  Amphora was generally safe and well tolerate

  4. Slide 4: Incidence of Sexually Transmitted Infections (U.S.) Increasing at an Alarming Annual Rate

    Incidence of Sexually Transmitted Infections (U.S.) Increasing at an Alarming Annual Rate CHLAMYDIA GONORRHEA 19% rate increase 1.8M 63% ~580K 1.4M rate increase ~350K 2014 2018 2014 2018 Source: Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. Atlanta: U.S

  5. Slide 5: Amphora Attributes & Mechanism of Action

    Amphora Attributes & Mechanism of Action Body • Investigational, non-hormonal, acid- pH Level 5 buffering MVP-R vaginal gel candidate with bio-adhesive properties Water pH Level 7 • Designed to maintain a natural acidic Semen/Blood vaginal pH of 3.5 to 4.5 pH Level 7.1 - 8 – Inhibits motility of spe

  6. Slide 6: Amphora: Potential to Impact Public Health

    Amphora: Potential to Impact Public Health 1.7M Annually1 Addressable Population AMPREVENCE Phase 2b 2019 2020 2021 2022 Clinical Trial Design Double-blinded, placebo-controlled efficacy trial Expected Anticipated Top-line Data at 50 U.S. sites Top-Line Expected Phase 3 Data Anticipated Initiation o

  7. Slide 7: AMPREVENCE: Top-line Phase 2b Results

    AMPREVENCE: Top-line Phase 2b Results CHLAMYDIA GONORRHEA 10 9.8% 9 8 50% Relative Risk 7 Reduction 6 5 4.9% 4 78% 3 3.2% Relative Risk Reduction 2 1 0.7% 0 Placebo Amphora Placebo Amphora Amphora was generally safe and well tolerated. Adverse events were similar across both arms (7.2% for Amphora a

  8. Slide 8: Significant Key Milestones and Next Steps

    Significant Key Milestones and Next Steps  Resubmitted Amphora NDA for the prevention of pregnancy to the FDA – Accelerating pre-commercial activities and launch preparations  Reported positive top-line results from the AMPREVENCE trial – Will be requesting an end-of-Phase 2 meeting with the FDA 

  9. Slide 9: ®

    ®

Evofem Biosciences — Technical Presentation (December 2019) on 6ix